Work

Clinical Activity and Pharmacokinetics (PK) of Cabozantinib (XL184) in Patients with Progressive Medullary Thyroid Carcinoma (MTC)

Year: 2012

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/s0923-7534(20)33071-4

Authors: E.E.W. Cohen, R. Elisei, M.J. Schlumberger, S.P. Müller, P. Schöffski, M. Brose, M. Shah, D.R. Miles, L.T. Nguyen, S. Sherman

Institutions: University of Chicago Medical Center, University of Pisa, Essen University Hospital, Universitair Ziekenhuis Leuven, University of Pennsylvania Health System, The Ohio State University, Exelixis (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Thyroid Cancer Diagnosis and Treatment

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2520475893

FWCI: 0.256

Cites:

Cited by: 3

Related to: 10